Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4QIOH)

• Drug Name: JSM 6427 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM4QIOH

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin beta-1 (ITGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
131I-radretumab	DMT17XU	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
OS2966	DMS8NM5	Glioblastoma of brain	2A00.00	Phase 1	[4]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[5]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[6]
MK-0668	DMVBFJP	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Integrin alpha-5 (ITGA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GW-559090	DM1FIN9	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[8]
TR-14531	DMH5SA6	Asthma	CA23	Discontinued in Phase 1	[9]
ZD-7349	DM1EB6H	Multiple sclerosis	8A40	Discontinued in Phase 1	[10]
DW-908e	DMXJ54Z	Allergy	4A80-4A85	Discontinued in Phase 1	[11]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5 (ITGA5)	TTHIZP9	ITA5_HUMAN	Antagonist	[2]
Integrin beta-1 (ITGB1)	TTBVIQC	ITB1_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT00536016) A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. U.S. National Institutes of Health.
• [2] An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
• [3] Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
• [4] Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40.
• [5] Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
• [6] Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.
• [7] Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
• [8] Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol. 2008 January; 83(1): 1-12.
• [9] US patent application no. US2010278784 (A1), Methods and compositions for treating skin conditions.
• [10] Eosinophil adhesion to cholinergic nerves via ICAM-1 and VCAM-1 and associated eosinophil degranulation. Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1279-88.
• [11] WO patent application no. 2008,1439,28, Methods and compositions for treating skin conditions.